1
|
Ringeleviciute U, Cernauskiene S, Zucenka A, Pileckyte R, Griskevicius L. TEMOZOLOMIDE, ETOPOSIDE, DOXIL, DEXAMETHASONE, IBRUTINIB AND RITUXIMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA IN CLINICAL PRACTICE. Hematol Oncol 2021. [DOI: 10.1002/hon.34_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- U Ringeleviciute
- Vilnius University Hospital Santaros Klinikos, Hematology, Oncology and Trasfusion Medicine Center Vilnius Lithuania
| | - S Cernauskiene
- Vilnius University Hospital Santaros Klinikos, Hematology, Oncology and Trasfusion Medicine Center Vilnius Lithuania
| | - A Zucenka
- Vilnius University Hospital Santaros Klinikos, Hematology, Oncology and Trasfusion Medicine Center Vilnius Lithuania
| | - R Pileckyte
- Vilnius University Hospital Santaros Klinikos, Hematology, Oncology and Trasfusion Medicine Center Vilnius Lithuania
| | - L Griskevicius
- Vilnius University Hospital Santaros Klinikos, Hematology, Oncology and Trasfusion Medicine Center Vilnius Lithuania
| |
Collapse
|
2
|
Valatkaite-Rakstiene B, Cekauskiene R, Griskevicius L, Jakubauskas A. Two novel HLA-C alleles, HLA-C*02:02:34 and HLA-C*03:369, were identified in the same individual. Int J Immunogenet 2018; 45:138-139. [PMID: 29663681 DOI: 10.1111/iji.12370] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2018] [Revised: 02/09/2018] [Accepted: 03/22/2018] [Indexed: 11/28/2022]
Abstract
Two new HLA class I alleles, HLA-C*02:02:34 and HLA-C*03:369, were characterized in a single Polish bone marrow donor.
Collapse
Affiliation(s)
- B Valatkaite-Rakstiene
- State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.,Haematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
| | - R Cekauskiene
- State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.,Haematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
| | - L Griskevicius
- Haematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.,Clinics of Internal, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - A Jakubauskas
- State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.,Haematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
| |
Collapse
|
3
|
Valatkaite-Rakstiene B, Cekauskiene R, Griskevicius L, Jakubauskas A. Identification of a novel allele, HLA-A*03:289, by sequence-based typing in Lithuanian patient. HLA 2018; 91:197-198. [PMID: 29292609 DOI: 10.1111/tan.13200] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Revised: 12/22/2017] [Accepted: 12/27/2017] [Indexed: 12/01/2022]
Abstract
Amino acid substitution Val165Leu of the HLA-A*03:01:01 results in a novel allele, HLA-A*03:289.
Collapse
Affiliation(s)
- B Valatkaite-Rakstiene
- State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.,Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
| | - R Cekauskiene
- State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.,Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
| | - L Griskevicius
- Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.,Clinics of Internal, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - A Jakubauskas
- State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.,Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
| |
Collapse
|
4
|
Valatkaite-Rakstiene B, Cekauskiene R, Griskevicius L, Jakubauskas A. Identification of a novel HLA-B*13 allele, HLA-B*13:99, by sequence-based typing in German bone marrow donor. HLA 2017; 89:158-159. [PMID: 28164462 DOI: 10.1111/tan.12974] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2017] [Revised: 01/16/2017] [Accepted: 01/17/2017] [Indexed: 11/29/2022]
Abstract
Amino acid substitution Glu277Lys of the HLA-B*13:02:09 results in a novel allele, HLA-B*13:99.
Collapse
Affiliation(s)
- B Valatkaite-Rakstiene
- State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.,Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania
| | - R Cekauskiene
- State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.,Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania
| | - L Griskevicius
- Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania.,Clinics of Internal, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - A Jakubauskas
- State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.,Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania
| |
Collapse
|
5
|
Brand B, Gruppo R, Wynn TT, Griskevicius L, Lopez Fernandez MF, Chapman M, Dvorak T, Pavlova BG, Abbuehl BE. Efficacy and safety of pegylated full‐length recombinant factor
VIII
with extended half‐life for perioperative haemostasis in haemophilia A patients. Haemophilia 2016; 22:e251-8. [DOI: 10.1111/hae.12963] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/25/2016] [Indexed: 11/27/2022]
Affiliation(s)
- B. Brand
- Universitaetsspital Zuerich Zuerich Switzerland
| | - R. Gruppo
- Cincinnati Children's Hospital Medical Center Cincinnati OHUSA
| | - T. T. Wynn
- College of Medicine University of Florida Gainesville FL USA
| | - L. Griskevicius
- Vilnius University Hospital Santariskiu Klinikos Medical Faculty of Vilnius University Vilnius Lithuania
| | | | | | - T. Dvorak
- Baxalta Innovations GmbH Vienna Austria
| | | | | |
Collapse
|
6
|
Rucinskas K, Cibiras S, Zurauskas E, Jakubauskas A, Daunoravicius D, Zasytyte I, Maneikiene V, Celutkiene J, Griskevicius L, Grabauskiene V. Non-Ischemic Dilated Cardiomyopathy: Biopsy Proved Markers of Disease Sub-Entities. J Heart Lung Transplant 2014. [DOI: 10.1016/j.healun.2014.01.723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
Jakubauskas A, Valatkaite B, Griskevicius L. Identification of a novel HLA-B allele, B*56:43, by sequence-based typing in a Lithuanian bone marrow donor. ACTA ACUST UNITED AC 2013; 83:59-60. [PMID: 24286123 DOI: 10.1111/tan.12250] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Accepted: 10/17/2013] [Indexed: 11/28/2022]
Abstract
A novel class I human leukocyte antigen allele HLA-B*56:43 is described.
Collapse
Affiliation(s)
- A Jakubauskas
- Department of Molecular and Regenerative Medicine, Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Vilnius, LT-08661, Lithuania
| | | | | |
Collapse
|
8
|
Jakubauskas A, Valatkaite B, Griskevicius L. Two novel HLA class II alleles, DRB1*11:131 and DQB1*05:01:05, identified by sequence-based typing. ACTA ACUST UNITED AC 2013; 82:299-300. [PMID: 24033271 DOI: 10.1111/tan.12196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Two novel class II human leukocyte antigen alleles HLA-DRB1*11:131 and HLA-DQB1*05:01:05 are described.
Collapse
Affiliation(s)
- A Jakubauskas
- Immunogenetics Unit; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania
| | | | | |
Collapse
|
9
|
Griskevicius A, Audzijoniene J, Griskevicius L, Petrulioniene Z, Laucevicius A. The lipoproteins selections aphereses with LDL Lipopak 400. Transfus Apher Sci 2013; 48:183. [DOI: 10.1016/j.transci.2013.02.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Griskevicius A, Audzijoniene J, Griskevicius L, Kasteckas M, Petrulioniene Z, Laucevicius A, Badariene J. P-55 THE LIPOPROTEINS SELECTIONS APHERESIS. Transfus Apher Sci 2012. [DOI: 10.1016/s1473-0502(12)70091-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
|
12
|
Jakubauskas A, Vilkeviciene R, Juskevicius D, Griskevicius L. Identification of a novel HLA-B allele, B*56:31, by sequence-based typing in a Lithuanian individual. Tissue Antigens 2011; 77:262-263. [PMID: 21299538 DOI: 10.1111/j.1399-0039.2010.01619.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
A novel allele HLA-B*56:31 differs from HLA-B*56:18 by three nucleotide substitutions resulting in a missense mutation Tyr171His (TAC to CAC) encoded in exon 3 and two silent substitutions at codon 188His (CAC to CAT) and codon 228Thr (ACT to ACC) encoded in exon 4.
Collapse
Affiliation(s)
- A Jakubauskas
- Department of Molecular and Regenerative Medicine, Hematology, Oncology, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania.
| | | | | | | |
Collapse
|
13
|
|
14
|
Jakubauskas A, Griskevicius L. Haplotype-specific sequencing reveals a novel HLA-A*03 allele, A*030114. Tissue Antigens 2010; 76:71-72. [PMID: 20136775 DOI: 10.1111/j.1399-0039.2010.01457.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The novel allele HLA-A*030114 differs from HLA-A*03010101 by a silent nucleotide substitution at codon 153A (GCG to GCA).
Collapse
Affiliation(s)
- A Jakubauskas
- Department of Molecular and Regenerative Medicine, Center of Hematology, Oncology and Transfusion Medicine, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania.
| | | |
Collapse
|
15
|
Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Gorczyca M, Andersen M, Nielsen T, Russell CA. Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.6520] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009; 50:374-9. [PMID: 19347726 DOI: 10.1080/10428190902756081] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Recombinant granulocyte colony-stimulating factors (G-CSFs) such as filgrastim or lenograstim are being used to treat chemotherapy-induced neutropenia. The aim of the present study was to investigate a new G-CSF, XM02, in comparison to filgrastim in terms of safety and efficacy in the prevention of chemotherapy-induced neutropenia in non-Hodgkin-lymphoma (NHL). A total of 92 patients receiving chemotherapy were randomised in cycle 1 to treatment with daily injections (subcutaneous 5 microg/kg/day) of XM02 (n = 63) or filgrastim (n = 29) for at least 5 days and a maximum of 14 days. In subsequent cycles, all patients received XM02. The mean duration of severe neutropenia (DSN) was 0.5 and 0.9 days in cycle 1 for XM02 and filgrastim, respectively (p = 0.1055). In cycle 1, the incidence of febrile neutropenia (FN) was 11.1% for XM02 and 20.7% for filgrastim (p = 0.1232). The adverse event profile was similar between XM02 and filgrastim. XM02 demonstrated equivalent efficacy and similar safety profile as the reference medication filgrastim. Treatment with XM02 is as beneficial as filgrastim in ameliorating severe neutropenia and FN in patients with NHL receiving chemotherapy. XM02 is safe and well tolerated in the doses applied in this study.
Collapse
Affiliation(s)
- A Engert
- Department of Internal Medicine, University Clinic of Cologne, Germany.
| | | | | | | | | |
Collapse
|
17
|
Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, Rane A. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003; 3:53-61. [PMID: 12629583 DOI: 10.1038/sj.tpj.6500157] [Citation(s) in RCA: 155] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The role of polymorphic CYP2B6 in cyclophosphamide (CPA) bioactivation was investigated in human liver microsomes. A total of 67 human liver specimens were first genotyped with respect to the CYP2B6*5 and CYP2B6*6 variant alleles. CYP2B6 apoprotein levels in 55 liver microsomal preparations were assessed by immunoblotting. 4-Hydroxy-CPA and hydroxy-bupropion were quantified by using HPLC and LC-MS, respectively. 7-Ethoxy-4-trifluoromethyl coumarin O-deethylase activity was measured fluorometrically. The frequencies of CYP2B6*5 and CYP2B6*6 mutant alleles were 9.0 and 16.4%, respectively. CYP2B6 protein expression was detected in 80% of the samples, with a large variation (0.003-2.234, arbitrary units). There was a high correlation between CYP2B6 apoprotein content and CPA 4-hydroxylation (n=55, r=0.81, P<0.0001). When based on the CYP2B6 apoprotein levels, the *6 carriers had significantly higher CPA 4-hydroxylation (P<0.05). CPA 4-hydroxylation also correlated significantly with other CYP2B6-specific reactions (n=20, P<0.0001). V(max) and K(m) for CPA 4-hydroxylation in recombinant CYP2B6 enzyme were 338 nmol/min/nmol enzyme and 1.4 mM, respectively. CYP2B6 showed much higher in vitro intrinsic clearance than previously observed in recombinant CYP2C19 and CYP2C9 variants in yeast expression system. Our results demonstrate that the polymorphic CYP2B6 is a major enzyme in the bioactivation of CPA. Moreover, we identified a strong impact of CYP2B6*6 on CPA 4-hydroxylation.
Collapse
Affiliation(s)
- H-J Xie
- Division of Clinical Pharmacology, Department of Medical Laboratory Sciences and Technology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
| | | | | | | | | | | | | |
Collapse
|
18
|
Xie HJ, Broberg U, Griskevicius L, Lundgren S, Carlens S, Meurling L, Paul C, Rane A, Hassan M. Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome p450 genes by ciprofloxacin. Bone Marrow Transplant 2003; 31:197-203. [PMID: 12621481 DOI: 10.1038/sj.bmt.1703815] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Recently, it has been reported that prophylactic administration of ciprofloxacin during cyclophosphamide (CY) conditioning was a high-risk factor for relapse in patients undergoing allogeneic BMT. In the present study, we investigated the possible mechanisms of this interaction in male Sprague-Dawley rats. The kinetics of CY and its active 4-OH-CY metabolite were determined, after 3 days pretreatment with ciprofloxacin (200 mg/kg) and compared to control rats without treatment. CY was administered as a high or low single intravenous dose (150 and 90 mg/kg, respectively). The expression of the CYP2B1, CYP2B2, CYP2C11, CYP3A1 and CYP3A2 genes was evaluated by SYBR Green I Dye real-time PCR for quantification of mRNA. The administration of ciprofloxacin resulted in a significant increase in the AUC (P=0.007) and a significant decrease in clearance (P=0.007) when CY was given as a high dose. In accordance, the metabolic ratio (AUC4-OH-CY/AUCCY) was significantly lower (P=0.007) compared to that found in the control group. Ciprofloxacin significantly suppressed gene expression of CYP2C11 (P=0.01) and CYP3A1 (P=0.04); however, no effect was observed on the gene expression of CYP3A2, CYP2B1 and CYP2B2. Our study revealed that ciprofloxacin interacts with CY and suppressed relevant cytochromes p450 at the transcriptional level. This study may have a great clinical impact when ciprofloxacin is used in therapy.
Collapse
Affiliation(s)
- H-J Xie
- Department of Medical Laboratory Sciences and Technology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
| | | | | | | | | | | | | | | | | |
Collapse
|